GPFA
HRTX icon

Game Plan Financial Advisors’s Heron Therapeutics HRTX Stock Holding History

Game Plan Financial Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$277 – 406
2024
Q1 		$277 Hold
100
– – ﹤0.01% 403
2023
Q4 		$170 Buy
+100
New +$110 ﹤0.01% 420

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Game Plan Financial Advisors's HRTX Position: Q2 2024 in Review

Game Plan Financial Advisors sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 100 shares — an estimated $277 sold.

Game Plan Financial Advisors first reported a position in HRTX in Q4 2023 and held it in 2 quarters. The position peaked at $277 in Q1 2024. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • Game Plan Financial Advisors reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Game Plan Financial Advisors sold 100 Heron Therapeutics shares in Q2 2024, an estimated $277.
  • Game Plan Financial Advisors first reported a position in Heron Therapeutics in Q4 2023 and held it in 2 quarters.
  • Game Plan Financial Advisors's Heron Therapeutics position peaked at $277 in Q1 2024.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on Game Plan Financial Advisors's 13F filing for Q2 2024, filed 1 Aug 2024.